Merck (MRK)Officer sold ~$616K

~$616K

Approx. value · 7,085 sh @ $87.00

Traded

Nov 10, 2025

Filed

Nov 12, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 29, 2024CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
2. Mar 19, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
3. Aug 4, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
4. Aug 5, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
5. Aug 14, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
6. Sep 19, 2025FDAFDA drug approval: Keytruda Qlex
7. Sep 19, 2025FDAFDA drug approval: Keytruda Qlex
8. Sep 23, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
9. Oct 15, 2025FDAFDA drug approval: Bla761495
10. Oct 24, 2025FDAFDA drug approval: Winrevair
11. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
12. Nov 3, 2025InsiderOfficer sold ~$720K of MRK shares in the open market
13. Nov 10, 2025 · this disclosureInsiderOfficer sold ~$616K of MRK shares in the open market

What came next

1. Nov 13, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
2. Nov 18, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
3. Nov 21, 2025FDAFDA drug approval: Keytruda
4. Nov 21, 2025FDAFDA drug approval: Keytruda Qlex
5. Dec 12, 2025FDARecall: Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 07065, USA, Manufactured…
6. Dec 12, 2025FDARecall: Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, Rx Only, Manufactured for: Merck Sharp & Doohme LLC, Rahway…
7. Dec 18, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
8. Dec 19, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
9. Jan 13, 2026Federal contract · $96K obligatedDepartment of Veterans Affairs awarded Merck: $96K obligated to date
10. Jan 27, 2026FDAFDA drug approval: Noxafil
11. Jan 27, 2026FDAFDA drug approval: Noxafil
12. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
13. Feb 4, 2026Insider · 4 peopleInsiders: 6 sales (~$13.2M)
14. Feb 5, 2026InsiderOfficer sold ~$2.44M of MRK shares in the open market
15. Feb 6, 2026Insider · 3 peopleInsiders: 3 sales (~$7.0M)
16. Feb 9, 2026Insider · 2 peopleInsiders: 4 sales (~$15.7M)
17. Feb 10, 2026FDAFDA drug approval: Keytruda
18. Feb 10, 2026FDAFDA drug approval: Keytruda Qlex
19. Feb 10, 2026InsiderOfficer sold ~$1.2M of MRK shares in the open market
20. Feb 12, 2026InsiderOfficer sold ~$1.21M of MRK shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Merck

For Merck, OQRO holds 26 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 123 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

Other recent filings by Cristal N Downing, Chief Comm. & Public Afrs Ofcr

• SEC Form 4 at Merck (MRK)Feb 7, 2025

The full history of Cristal N Downing, Chief Comm. & Public Afrs Ofcr is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Merck

• House Clerk periodic transaction reportOct 7, 2026
• USAspending.gov award recordSep 17, 2026
• House Clerk periodic transaction reportSep 9, 2026
• House Clerk periodic transaction reportSep 9, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 25, 2026

Everything OQRO holds on this company is on its MRK page.